297 results about "Venom" patented technology

The invention relates to a preparation method of Muscovy duck parvo novel vaccines, which comprises the following steps of: using Muscovy duck parvovirus attenuated virus P1 strain (MPV-P1 strain with a preservation number of CCTCC NO:V201013) and Muscovy duck origin goose parvovirus attenuated virus D strain ( GPV-D strain with a preservation number of CCTCC NO:V201014) as seed viruses; proliferating viruses by applying the muscovy duck embryone fibroblast spinner culture technology to obtain cell toxic liquids; mixing the cell toxic liquids according to the proper proportion and freezing a dry protective agent to freeze and dry to research safe and effective Muscovy duck parvo novel vaccines. The young Muscovy ducks are inoculated once so as to prevent and control the Muscovy duck parvovirus infection and the Muscovy duck gosling blast dieases at the same time, thereby the stress reaction of the Muscovy ducks caused by immunization for many times is solved. The invention is suitable for scale production under the GMP (Good Manufacturing Practices) condition, and saves the production cost of the vaccines.

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3′-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate. For example, if the protein in the DNA-protein conjugate is the first component of the complement cascade (Clq or Clqrs) and the DNA aptamer has been developed against surface components of a target cell, it can be used to treat bacterial or parasitic infections and cancers. If the protein is serum albumin or another common (nonimmunogenic) blood protein and the aptamer is directed against a toxin or venom, the aptamer-protein conjugate can be used as an antidote that binds and neutralizes the toxin or venom. Similar DNA (aptamer)-nanotube, -enzyme, and -toxin conjugates could also be used to target and selectively kill bacteria, parasites, and cancer cells in vivo. If the protein is an Fc antibody fragment or C3b protein from the complement system and the aptamer is developed against a bacterial cell capsular material, other cell surface component or viral cell surface component, then the aptamer-3′-protein conjugate can aid in opsonization of the target cells or viruses by phagocytic leukocytes.

A hemostatic composition which comprises at least one procoagulant metal ion, such as silver (I) or mercury (II), and at least one procoagulant biopolymer, such as collagen, thrombin, prothrombin, fibrin, fibrinogen, heparinase, Factor VIIa, Factor VIII, Factor IXa, Factor Xa, Factor XII, von Willebrand Factor, a selectin, a procoagulant venom, a plasminogen activator inhibitor, glycoprotein IIb-IIIa, a protease, or plasma. The composition in the form of a paste, dough, glue, liquid, lyophilized powder or foam, may be provided, for application to a wound. A hemostatic device is also described which comprises a hemostatic composition as described above. The device may be in the form of, for example, a plug, bandage, gauze, cloth, tampon, membrane or sponge. Methods are also provided for prophylaxis or treatment of bleeding at a site by application to the site of the composition or device as described.

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The α-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

The invention is a preparing method of the low-molecular chitosan quaternary-ammonium-salt complex iodine sterilizing solution, its character: mixing and agitating the low-molecular chitosan quaternary-ammonium-salt or low-molecular chitosan solution with one, two or all of dialkyl diquaterary ammonium salt, dialkyl quaterary ammonium salt, and methyl quaterary ammonium salt, then heating the mixed solution, adding with iodine, or iodine and iodate, preserving heat to react, and cooling to room temperature. It is an environmental-protection, strong-efficiency disinfectant, irritation and the toxicity lower, and the sterilizing effect more stable and permanent.

The invention discloses application of a baby hamster kidney(BHK)-21 cell serum-free suspension culture technology in foot-and-mouth disease vaccine production, which comprises the following steps of: 1) performing cell recovery; 2) performing reactor culture and cell amplification culture; and 3) inoculating foot-and-mouth disease virus seed venom and collecting the venom. A process for producing foot-and-mouth disease inactivated vaccines by culturing the BHK-21 cells through serum-free suspension culture and a step-by-step cell amplification method make the production period f the foot-and-mouth disease vaccines shortened and yield increased, and ensure stable quality and obvious benefit. The production process reduces the using amount of a culture medium, and the amount of the collected virus liquid is the culture medium consumption amount, while the culture medium consumption amount in a roller bottle production process is 2 times higher than the amount of the collected virus liquid, and bovine serum which is about 5 percent of the culture medium amount is needed.

The invention discloses a production method for vaccines of avian influenza virus and other influenza virus such as swine influenza, dog influenza and equine influenza, which comprises the following steps of: (1) transfer of culture and cultivation of vaccine-made cells; (2) reproduction of vaccine-made virus seeds; (3) microcarrier suspension culture of MDCK cells in a bioreactor; (4) reproduction of vaccine-made virus liquid; and (5) harvest of the virus liquid. The production method has the advantages of reducing the production cost greatly and improving the yield and quality of the vaccines obviously, along with short production period, no restriction to raw material supply, small occupied area, easy and quick expansion of production scale, light environmental pollution, easy processing, high automaticity, low employment and easy realization of balanced and stable quality.

The present invention relates to a medicine for curing malignant tumor and its preparation method. It is made of asparagus tuber, Buddha's hand fruit, American ginseng, acanthopanax obovatus, hippophae rhmnoides fruit, Chinese gooseberry root, venom and bolbostemma tuber as raw material through the processes of removing dust and cleaning, decocting, alcohol precipitation extraction and alcohol impregnating extraction. Said medicine has no toxic side effect, has strong action of resisting tumor and raising immunity of body, and can possess synergistic action and attenuation when it is matched with radiotherapy and chemical medicine therapy to cure malignant tumor, and can obtain good therapeutic effect.

The invention discloses a method for preparing a rainbow trout IHN (Infectious Haematopoietic Necrosis) inactivated vaccine, which comprises the following steps: carrying out grinding, filtering and poison dipping processing on pancreas and livers of juvenile fish which is attacked, but is still alive, inoculating rainbow trout gonad (RTG) cells, carrying out blind passaging at 14 DEG C, keeping for 5 days when carrying out blind passaging on the tenth generation, and collecting cell poisonous fluid; inoculating chinook salmon embryonic (CHSE) cells, carrying out passaging at 14 DEG C, and raising the culture temperature by 1 DEG C when passaging for 5 generations each time until the culture temperature is raised to 20 DEG C; and adopting epithelioma papulosum cyprini (EPC) cells to continuously carry out passaging under the condition of 20 DEG C, passaging to the twelfth generation to obtain high-titer virus solution and carrying out inactivation to obtain the rainbow trout IHN inactivated vaccine. According to the preparation method, RTG-2, CHSE-214 and EPC cells are utilized to alternately culture rainbow trout IHN viruses at a specific environment temperature so as to obtain a high-titer IHNV (Infectious Hematopoietic Necrosis Virus) antigen and produce the inactivated vaccine; and the technical difficult problem that the high-titer IHNV antigen cannot be obtained through single cells is solved.

The invention belongs to the technical field of biological products for veterinary use, in particular to a method for preparing a swine fever-pseudorabies bigeminal live vaccine by using passage cells and a product thereof. The method for preparing the swine fever-pseudorabies bigeminal live vaccine by using the passage cells comprises the following steps: (1) culturing a swine fever lentogen strain and a pseudorabies lentogen strain by the passage cells; (2) harvesting cell culture venoms prepared in the step (1); and (3) mixing two kinds of cell culture venoms prepared in the step (2) in a ratio of 1:2 to prepare the passage cell swine fever-pseudorabies bigeminal live vaccine through cooling and vacuum drying. The invention also provides the swine fever-pseudorabies bigeminal live vaccine prepared by the preparation method. The swine fever-pseudorabies bigeminal live vaccine can be used for immunization, can reduce the workload of the immunization, reduce the number of immunization times, avoid immunologic paralysis caused by frequent immunizations, reduce stress on a swine herd correspondingly, and prevent and control the occurrence of the swine fever and the pseudorabies.

The invention discloses mass production of inactivated vaccine of porcine circovirus II (PCV2) and a preparation method thereof. The preparation method comprises the following technical steps: (1) high-density culture of cells for vaccine preparation; (2) reproduction of venom for vaccine preparation; and (3) addition of adjuvant to prepare the inactivated vaccine. Compared with the prior art, the invention has the advantages that the virus yield is high, the virus titer is high, the production scale is large, the yield of a single batch is high, the production cost is relatively low, the product quality is high and stable, the operation is convenient, the operation space is small, the technological parameters are controlled accurately and the like. The inactivated vaccine has high safety, can induce pig bodies to generate immune protection and fully satisfies the national biological product standards.

The invention discloses a medicine for external application for treating pyogenic type contaminated wounds, which is characterized by comprising the following raw materials in the proportion by weight: 20-60 of catechu, 15-45 of dragon blood, 25-60 of prepared frankincense, 25-60 of prepared myrrh, 50-150 of calcined dragon bone, 60-200 of calcined gypsum, 20-60 of red halloysite, 40-80 of pearl, 0.5-1.0 of musk, 2-5 of borneol and 2-5 of calomel. The medicine for external application has the efficacies of diminishing inflammation and relieving pain, removing necrosis and promoting granulation, promoting discharge of venom, increasing the amount of blood supply, activating cell growth, accelerating growth of granulation tissue and promoting wounds to heal quickly. The medicine for external application is used for treating various pyogenic type contaminated wounds of dermis, fat, muscle, aponeurosis and periosteum. After clinical application for many years, the medicine for external application has good treating effect, and the healing rate reaches 90 percent. The course of treatment is generally ten days to two months, the healed wounds have unobvious scars, and patients have slight or no functional disorder.

The present invention relates to a class of proteins, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified modified venom composition.

The herein invention refers to a purifying process of soluble proteins of the L. obliqua bristles through prothrombin activation; a partial deterrination of the amino acids sequence of the prothrombin activator; a process for determining the fraction II of the prothrombin activation as well as the N-terminal sequence and the sequence of internal fragments of the prothrombin activator fraction, the prothrombin activator and the utilization of the prothrombin activator through the homogenization of the L. obliqua bristles. The herein invention has shown that only one component of the Lonomia obliqua venom, the Lopap, causes the hemorrhagic syndrome directly by activating prothrombin and, therefore, a patient should be conducted to a therapy when in contact with the Lonomia obliqua venom. According to the herein invention, Lopap is a new prothrombin activator, showino to be a quite important factor responsible for consumption coagulopathy, found in patients exposed to the venom of the L. obliqua caterpillar. In low doses of purified protein, due to its capacity of activating prothrombin and generating thrombin, it is possible, in controlled conditions, to withdraw fibrinogen from circulation, transforming it in fibrin microthrombs. The decrease on the concentration of plasmatic fibrinogen promotes the increasing of blood coagulation time and therefore it will avoid acute vascular thrombosis. Since protein does not present proteolytic activity, it could maintain the coagulating capacity of the fibrinogen not consumed in the process. The fibrinogen plasmatic concentration would decrease, however there would not be predisposition for hemorrhagic state. Besides that, it could be used to produce diagnosis KITS for detecting dysprothrombinemias.

The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The

The invention discloses a Newcastle disease-H9 subtype avian influenza bivalent dual-adjuvant inactivated vaccine and a preparation method thereof. The bivalent vaccine consists of a concentrated and inactivated ND and AI (H9) venom, levamisole hydrochloride and an oil adjuvant, wherein every milliliter of inactivated vaccine contains 0.5-16 mg of levamisole hydrochloride immunopotentiator. When the synergic ND-AI (H9) bivalent dual-adjuvant inactivated vaccine prepared with the method is applied to immunized chicken, the humoral immunity and cell immune levels of table poultry and laying hens can be raised effectively, the growth is promoted, and rate of live weight growth is increased. The bivalent dual-adjuvant inactivated vaccine has an immune effect which is remarkably superior to that of the conventional chicken ND-AI bivalent oil emulsion inactivated vaccine, and can be used for effectively protecting chicken flocks from being intruded by the ND virus and AI (H9) virus and preventing the Newcastle disease and H9 subtype avian influenza at the immune period.

The invention discloses a triple vaccine special for Muscovy duck, and the triple vaccine special for Muscovy duck uses Muscovy duck liver white-spot disease attenuated MWCA strain, Muscovy duck parvovirus attenuated P1 strain and Muscovy duck goose-origin parvovirus attenuated D strain as seed viruses, and respectively uses SPF chicken embryo fibroblast or Muscovy duck embryo fibroblast spinner cultivation technology to propagate virus and obtain the cell toxic liquid, and after mixing according to a proper proportion, a freeze-drying protective agent is added for freeze drying, and the triple live vaccine of Muscovy duck reovirus disease, Muscovy duck parvovirus disease and Muscovy duck gosling plague special for Muscovy duck is prepared; the triple vaccine can be used in the Muscovy duck culture region where the Muscovy duck reovirus disease, the Muscovy duck parvovirus disease and the Muscovy duck gosling plague are prevalent, and the purpose for preventing and controlling three diseases above can be realized by one-time immunization.